Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07693907

A Taiwan-Adapted Self-Management Program for Adults With Irritable Bowel Syndrome

This pilot randomized controlled trial will evaluate the feasibility, acceptability, and preliminary effects of a Taiwanese version of a comprehensive self-management program for adults with irritable bowel syndrome. Participants will be randomized to the self-management program or usual care. Outcomes will be assessed at baseline, immediately after the intervention, and three months after the intervention.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Irritable Bowel Syndrome Colonic Diseases Colonic Diseases, Functional Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The study will enroll adults with irritable bowel syndrome and randomize participants in a 2:1 ratio to an 8-session comprehensive self-management program or usual care. The program includes irritable bowel syndrome education, symptom monitoring, relaxation practice, cognitive strategies, dietary self-management, sleep-related content, problem solving, and daily-life symptom management. The pilot trial will assess recruitment, retention, intervention adherence, acceptability, satisfaction, and preliminary changes in symptom-related outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 20 to 70 years

  • Meets Rome criteria for irritable bowel syndrome
  • Has a healthcare provider diagnosis of irritable bowel syndrome
  • Able to read and speak Mandarin
  • Willing to provide informed consent and participate in study procedures

Exclusion criteria

  • Pregnant or breastfeeding
  • Poorly controlled mental health problems, including history of psychosis, bipolar disorder, drug or alcohol abuse or dependence, or suicide attempt within the past 2 years unless explained by significant loss
  • Surgery or hospitalization within the past month
  • Unable to complete study questionnaires or study procedures
  • Unable to complete study questionnaires or study procedures -

Treatment and study plan

Comprehensive Self-Management Program

Behavioral

Participants assigned to the intervention group will receive an 8-session comprehensive self-management program over approximately 8 weeks. The program includes irritable bowel syndrome education, symptom monitoring, relaxation practice, cognitive strategies, dietary self-management, sleep-related content, problem solving, and daily-life symptom management.

Usual Care

Other

Participants assigned to the usual care group will continue to receive usual clinical care and complete scheduled study assessments.

Primary outcomes

  1. Proportion of Participants Who Complete the 3-Month Follow-Up Assessment

    Time frame: From enrollment to 3 months post-intervention

    The proportion of enrolled participants who complete the 3-month post-intervention assessment will be calculated.

  2. Proportion of Intervention Sessions Completed

    Time frame: From Week 1 to Week 8

    The proportion of assigned intervention sessions completed by participants in the comprehensive self-management program group will be calculated.

  3. Mean Acceptability Score Immediately Post-Intervention

    Time frame: Immediately post-intervention

    Acceptability of the study procedures and intervention will be assessed using investigator-developed acceptability items. Higher scores indicate greater acceptability.

  4. Proportion of Participants With Complete Questionnaire Data

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    The proportion of participants with complete questionnaire data at each assessment time point will be calculated.

Secondary outcomes

  1. Change From Baseline in Irritable Bowel Syndrome Quality of Life Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Irritable bowel syndrome-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire. Total scores range from 0 to 100, with higher scores indicating better quality of life.

  2. Change From Baseline in Irritable Bowel Syndrome Symptom Severity Scale Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Irritable bowel syndrome symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale. Total scores range from 0 to 500, with higher scores indicating greater symptom severity.

  3. Change From Baseline in Percentage of Days With Moderate to Very Severe Gastrointestinal Symptoms Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Daily gastrointestinal symptoms will be assessed using a daily symptom diary over 2 weeks. The score will be calculated as the percentage of days with at least one moderate to very severe gastrointestinal symptom, ranging from 0% to 100%. Higher percentages indicate more frequent moderate to very severe gastrointestinal symptoms.

  4. Change From Baseline in Patient-Reported Outcomes Measurement Information System Fatigue T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System Fatigue scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater fatigue.

  5. Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Sleep disturbance will be assessed using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater sleep disturbance.

  6. Change From Baseline in Patient-Reported Outcomes Measurement Information System Anxiety T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Anxiety symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System Anxiety scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater anxiety symptoms.

  7. Change From Baseline in Patient-Reported Outcomes Measurement Information System Depression T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System Depression scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater depressive symptoms.

  8. Change From Baseline in Visceral Sensitivity Index Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Gastrointestinal symptom-specific anxiety will be assessed using the Visceral Sensitivity Index. Total scores range from 0 to 75, with higher scores indicating greater gastrointestinal symptom-specific anxiety.

  9. Change From Baseline in Work Productivity and Activity Impairment Percentage Immediately Post-Intervention and at 3 Months Post-Intervention

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

    Work productivity and activity impairment will be assessed using the Work Productivity and Activity Impairment Questionnaire-Irritable Bowel Syndrome. Scores are reported as percentages from 0% to 100%, with higher percentages indicating greater impairment.

  10. Proportion of Participants Reporting Use of at Least One Self-Management Strategy at 3 Months Post-Intervention

    Time frame: 3 months post-intervention

    Use of self-management strategies will be assessed by asking participants how often they use each strategy. The proportion of participants reporting use of at least one self-management strategy will be calculated.

  11. Change From Baseline in Gut Microbiome Shannon Diversity Index Immediately Post-Intervention

    Time frame: Baseline and immediately post-intervention

    Gut microbiome Shannon diversity index will be calculated from stool samples using 16S ribosomal RNA gene sequencing. Higher values indicate greater within-sample microbial diversity.

  12. Change From Baseline in Gut Microbiome Richness Immediately Post-Intervention

    Time frame: Baseline and immediately post-intervention

    Gut microbiome richness will be calculated from stool samples using 16S ribosomal RNA gene sequencing. Higher values indicate a greater number of observed microbial taxa.

  13. Change From Baseline in Fecal Calprotectin Concentration Immediately Post-Intervention

    Time frame: Baseline and immediately post-intervention

    Fecal calprotectin concentration will be measured from stool samples using enzyme-linked immunosorbent assay. Results will be reported in micrograms per gram of stool, with higher values indicating greater intestinal inflammation.

Study contacts

Contact information is provided by the study sponsor or research team.

Pei-Lin Yang, PhD

CONTACT

[email protected]

+886-2-8792-3100 ext. 18778

Sponsors and collaborators

Lead sponsor

National Defense Medical Center, Taiwan

Other

Collaborators

  • National Health Research Institutes, Taiwan
  • Tri-Service General Hospital (TSGH)

Registry information

Official study title

A Pilot Randomized Controlled Trial of a Taiwanese Version of a Comprehensive Self-Management Program for Adults With Irritable Bowel Syndrome

Acronym: CSM-T-IBS

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jul 9, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.